Display options
Cite
Youssef LA, Schuyler M, Wilson BS, et al. Roles for the High Affinity IgE Receptor, FcεRI, of Human Basophils in the Pathogenesis and Therapy of Allergic Asthma: Disease Promotion, Protection or Both?. Open Allergy J. 2010;3:91-101doi: 10.2174/1874838401003010091.
Youssef, L. A., Schuyler, M., Wilson, B. S., & Oliver, J. M. (2010). Roles for the High Affinity IgE Receptor, FcεRI, of Human Basophils in the Pathogenesis and Therapy of Allergic Asthma: Disease Promotion, Protection or Both?. The open allergy journal, 391-101. https://doi.org/10.2174/1874838401003010091
Youssef, Lama A, et al. "Roles for the High Affinity IgE Receptor, FcεRI, of Human Basophils in the Pathogenesis and Therapy of Allergic Asthma: Disease Promotion, Protection or Both?." The open allergy journal vol. 3 (2010): 91-101. doi: https://doi.org/10.2174/1874838401003010091
Youssef LA, Schuyler M, Wilson BS, Oliver JM. Roles for the High Affinity IgE Receptor, FcεRI, of Human Basophils in the Pathogenesis and Therapy of Allergic Asthma: Disease Promotion, Protection or Both?. Open Allergy J. 2010;3:91-101. doi: 10.2174/1874838401003010091. PMID: 25018787; PMCID: PMC4090948.
Copy Download .nbib Format: NLM
Share it on

Open Allergy J. 2010;3:91-101. doi: 10.2174/1874838401003010091.

Roles for the High Affinity IgE Receptor, FcεRI, of Human Basophils in the Pathogenesis and Therapy of Allergic Asthma: Disease Promotion, Protection or Both?.

The open allergy journal

Lama A Youssef, Mark Schuyler, Bridget S Wilson, Janet M Oliver

Affiliations

  1. Department of Pharmaceutics and Pharmaceutical Technology, Damascus University, Damascus, Syria.
  2. Departments of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
  3. Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.

PMID: 25018787 PMCID: PMC4090948 DOI: 10.2174/1874838401003010091

Abstract

The role of basophils, the rarest of blood granulocytes, in the pathophysiology of allergic asthma is still incompletely understood. Indirect evidence generated over many decades is consistent with a role for basophils in disease promotion. Recent improvements in procedures to purify and analyze very small numbers of human cells have generally supported this view, but have also revealed new complexities. This chapter focuses on our analyses of Fcε R1 function in basophils in the context of understanding and treating human allergic asthma. In long-term studies, we demonstrated that asthmatic subjects have higher circulating numbers of basophils than non-atopic non-asthmatic subjects and that their basophils show higher rates of both basal and anti-IgE or antigen-stimulated histamine release. These results hint at a direct role for basophils in promoting asthma. Supporting this interpretation, the non-releaser phenotype that we linked to the excessive proteolysis of Syk via the ubiquitin/proteasomal pathway is less common in basophils from asthmatic than non-asthmatic donors. The discovery of a basophil-specific pathway regulating Syk levels presents a clear opportunity for therapy. Another route to therapy was revealed by evidence that basophil FcεRI signaling can be downregulated by co-crosslinking the ITAM-containing IgE receptor, FcγRI, to the ITIM-containing IgG receptor, FcγRIIB. Based on this discovery, hybrid co-crosslinking fusion proteins are being engineered as potential therapies targeting basophils. A third distinguishing property of human basophils is their high dependence on IgE binding to stabilize membrane FcεRI. The circulating IgE scavenging mAb, Omalizumab, reduces FcεRI expression in basophils from asthmatics by over 95% and produces a substantial impairment of IL-4, IL-8 and IL-13 production in response to the crosslinking of residual cell surface IgE-FcεRI. A search for small molecule inhibitors that similarly impair high affinity IgE binding to basophils may yield reagents that mimic Omalizumab's therapeutic benefits without the potential for immune side effects. Although studies on allergen and FcεRI-mediated basophil activation all point to a role in promoting disease, a case can also be made for an alternative or additional role of basophil FcεRI in protection against allergic asthma. Human basophils have high affinities for IgE, they upregulate receptor levels over a >100-fold range as circulating IgE levels increase and they have short half-lives in the circulation. Thus, when allergen is absent, basophil FcεRI could serve as scavengers of serum IgE and therefore protectors against mast cell IgE-mediated inflammatory responses. Further studies are clearly needed to determine if FcεR-expressing basophils play pathogenic or protective roles - or both - in human allergic asthma and other IgE-mediated inflammatory disorders.

Keywords: Allergic asthma; FcεRI; IgE; basophils; pathogenesis; therapy

References

  1. J Immunol. 1997 Feb 1;158(3):1438-45 - PubMed
  2. Immunity. 2005 Aug;23(2):191-202 - PubMed
  3. Inflamm Res. 2004 May;53(5):181-8 - PubMed
  4. Blood. 2008 Nov 15;112(10):3949-58 - PubMed
  5. N Engl J Med. 1999 Dec 23;341(26):1966-73 - PubMed
  6. J Immunol. 1999 May 1;162(9):5624-30 - PubMed
  7. J Asthma. 1996;33(2):89-95 - PubMed
  8. J Biol Chem. 1995 Feb 24;270(8):4013-22 - PubMed
  9. J Biol Chem. 2001 Dec 28;276(52):48670-8 - PubMed
  10. Am J Respir Cell Mol Biol. 1994 Apr;10(4):384-90 - PubMed
  11. Mol Cell Biol. 1992 Jul;12(7):3176-82 - PubMed
  12. Blood. 2007 Aug 1;110(3):913-20 - PubMed
  13. Allergy. 2004 May;59(5):469-78 - PubMed
  14. J Leukoc Biol. 2001 Nov;70(5):776-82 - PubMed
  15. J Allergy Clin Immunol. 2002 Sep;110(3):366-73 - PubMed
  16. Nature. 1993 Sep 23;365(6444):340-3 - PubMed
  17. Int Arch Allergy Immunol. 2008;145(3):182-92 - PubMed
  18. J Immunol. 1999 Oct 1;163(7):3976-84 - PubMed
  19. J Allergy Clin Immunol. 2007 Aug;120(2):462-8 - PubMed
  20. Clin Exp Allergy. 1990 Nov;20(6):661-8 - PubMed
  21. Nat Immunol. 2002 Jul;3(7):681-6 - PubMed
  22. Clin Exp Allergy. 2005 Apr;35(4):408-16 - PubMed
  23. Nat Med. 2002 May;8(5):518-21 - PubMed
  24. Int Immunol. 2000 Feb;12(2):169-76 - PubMed
  25. Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12539-44 - PubMed
  26. J Allergy Clin Immunol. 1998 Aug;102(2):304-15 - PubMed
  27. J Immunol Methods. 1994 Sep 30;175(1):1-9 - PubMed
  28. Am Rev Respir Dis. 1991 Jul;144(1):51-8 - PubMed
  29. Vital Health Stat 10. 2012 Dec;(254):1-88 - PubMed
  30. J Allergy Clin Immunol. 2000 Oct;106(4):677-86 - PubMed
  31. Nat Rev Immunol. 2007 May;7(5):365-78 - PubMed
  32. Nat Immunol. 2008 Jul;9(7):733-42 - PubMed
  33. J Allergy Clin Immunol. 2000 Aug;106(2):337-48 - PubMed
  34. Am J Respir Crit Care Med. 2001 Sep 15;164(6):1053-8 - PubMed
  35. J Leukoc Biol. 2001 Aug;70(2):207-18 - PubMed
  36. Int Arch Allergy Immunol. 1993;101(2):196-202 - PubMed
  37. Nat Immunol. 2009 Jul;10(7):713-20 - PubMed
  38. J Immunol. 2007 Apr 1;178(7):4584-94 - PubMed
  39. J Biol Chem. 1994 Nov 25;269(47):29697-703 - PubMed
  40. J Exp Med. 1993 Mar 1;177(3):605-11 - PubMed
  41. Nat Med. 2005 Apr;11(4):446-9 - PubMed
  42. J Allergy Clin Immunol. 1999 Aug;104(2 Pt 1):279-84 - PubMed
  43. J Immunol. 2000 Nov 15;165(10):5913-20 - PubMed
  44. J Biol Chem. 2006 Jun 23;281(25):17108-17113 - PubMed
  45. J Immunol. 1999 Jan 1;162(1):176-85 - PubMed
  46. J Allergy Clin Immunol. 2006 Jun;117(6):1230-2 - PubMed
  47. Nat Immunol. 2008 Mar;9(3):310-8 - PubMed
  48. J Immunol. 1996 Jun 15;156(12):4833-8 - PubMed
  49. Int Arch Allergy Immunol. 2010;151(4):275-84 - PubMed

Publication Types

Grant support